Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ibilola Fashoyin"'
Autor:
David J. James Pinato, Xiaoxue Li, Pallavi Shruti Mishra-Kalyani, Antonio D'Alessio, Claudia A.M. Fulgenzi, Guo Wei, Julie A. Schneider, Donna Rivera, Richard Pazdur, Marc Robert Theoret, Sandra J. Casak, Steven Lemery, Ibilola Fashoyin, Alessio Cortellini, Lorraine Cheryl Pelosof
Publikováno v:
Journal of Clinical Oncology. 40:4089-4089
4089 Background: Immune checkpoint inhibitors (ICI) alone or in combination with tyrosine kinase (TKI) or VEGF pathway inhibitors (VEGFi) are therapeutic options in unresectable HCC (uHCC). Whether exposure to antibiotics (ATB), a consolidated advers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5527bce2cbb0d8394b364d11f572bcf7
https://doi.org/10.1200/jco.2022.40.16_suppl.4089
https://doi.org/10.1200/jco.2022.40.16_suppl.4089
Autor:
Rachel Novak, Michele Dougherty, Sarah Kennett, Sachia Khasar, Hongshan Li, Steven Lemery, Kun He, Patricia Keegan, Hong Zhao, Whitney Helms, Richard Pazdur, Runyan Jin, Hui Zhang, L. Zhang, Liang Zhao, Ibilola Fashoyin-Aje, Sandra J. Casak, Huanyu Chen
Publikováno v:
Clinical Cancer Research. 21:3372-3376
The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma initially as monotherapy (April 21, 2014) and subsequently as combination th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7260a69dc1a56105c15ce8a26ed1c1e2
https://doi.org/10.1158/1078-0432.ccr-15-0600
https://doi.org/10.1158/1078-0432.ccr-15-0600
Publikováno v:
American Journal of Gastroenterology. 102:S209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ba827d6f189ed1740926bdee9e646ca
https://doi.org/10.14309/00000434-200709002-00252
https://doi.org/10.14309/00000434-200709002-00252